Dyne Therapeutics, Inc.
Company Stats
- Market Cap
- $3.0B
- as of Sep 30, 2026
- Enterprise Value
- $2.3B
- Shares Outstanding
- 186.7M
- Free Float
- 95.1%
Income Statement
- Operating Income
- -$468.2M
- Net Income
- -$446.2M
- EBITDA
- -$466.1M
Cash Flow
- Free Cash Flow
- -$405.1M
- FCF Yield
- -13.5%
- Owner FCF Yield
- -15.0%
Balance Sheet
- Cash & Equivalents
- $893.4M
- Total Debt
- $150.0M
- Net Cash
- $743.4M
Returns & Capital
- SBC, 3Y Avg
- $37.2M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$405.1M | — |
| FY2024 | — | -$294.7M | — |
| FY2023 | — | -$188.9M | — |
| FY2022 | — | -$156.7M | — |
| FY2021 | — | -$123.2M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of November 5, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Drug Pricing and PBM Scrutiny: Medicare Rulemaking Gains Detail
Stronger demand supports expansion as pricing diverges